ImmunoPrecise Antibodies Ltd (IPA)
0.4599
-0.02
(-4.19%)
USD |
NASDAQ |
Nov 14, 16:00
0.50
+0.04
(+8.72%)
After-Hours: 20:00
ImmunoPrecise Antibodies Enterprise Value: 11.89M for Nov. 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 14, 2024 | 11.89M |
| November 13, 2024 | 12.45M |
| November 12, 2024 | 12.17M |
| November 11, 2024 | 11.55M |
| November 08, 2024 | 11.33M |
| November 07, 2024 | 11.33M |
| November 06, 2024 | 10.03M |
| November 05, 2024 | 10.82M |
| November 04, 2024 | 11.06M |
| November 01, 2024 | 10.71M |
| October 31, 2024 | 12.37M |
| October 30, 2024 | 12.65M |
| October 29, 2024 | 14.17M |
| October 28, 2024 | 15.13M |
| October 25, 2024 | 17.98M |
| October 24, 2024 | 15.10M |
| October 23, 2024 | 14.00M |
| October 22, 2024 | 13.21M |
| October 21, 2024 | 13.99M |
| October 18, 2024 | 14.13M |
| October 17, 2024 | 14.10M |
| October 16, 2024 | 14.71M |
| October 15, 2024 | 14.96M |
| October 14, 2024 | 15.15M |
| October 11, 2024 | 15.47M |
| Date | Value |
|---|---|
| October 10, 2024 | 15.52M |
| October 09, 2024 | 15.55M |
| October 08, 2024 | 16.60M |
| October 07, 2024 | 16.36M |
| October 04, 2024 | 16.50M |
| October 03, 2024 | 14.20M |
| October 02, 2024 | 15.32M |
| October 01, 2024 | 15.37M |
| September 30, 2024 | 16.89M |
| September 27, 2024 | 17.13M |
| September 26, 2024 | 17.75M |
| September 25, 2024 | 18.03M |
| September 24, 2024 | 17.11M |
| September 23, 2024 | 16.99M |
| September 20, 2024 | 17.75M |
| September 19, 2024 | 17.89M |
| September 18, 2024 | 17.48M |
| September 17, 2024 | 15.21M |
| September 16, 2024 | 14.18M |
| September 13, 2024 | 17.75M |
| September 12, 2024 | 16.52M |
| September 11, 2024 | 16.39M |
| September 10, 2024 | 16.96M |
| September 09, 2024 | 16.82M |
| September 06, 2024 | 17.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
10.03M
Minimum
Nov 06 2024
303.24M
Maximum
Dec 29 2020
81.08M
Average
75.03M
Median
Jun 15 2022
Enterprise Value Benchmarks
| Aurinia Pharmaceuticals Inc | 843.94M |
| Edesa Biotech Inc | 5.103M |
| Lexaria Bioscience Corp | 24.64M |
| Xenon Pharmaceuticals Inc | 2.442B |
| ESSA Pharma Inc | -52.60M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.920M |
| Revenue (Quarterly) | 3.842M |
| Total Expenses (Quarterly) | 7.220M |
| EPS Diluted (Quarterly) | -0.1095 |
| Gross Profit Margin (Quarterly) | 44.77% |
| Profit Margin (Quarterly) | -75.98% |
| Earnings Yield | -169.7% |
| Normalized Earnings Yield | -82.88 |